Search

Your search keyword '"Joseph JY Sung"' showing total 14 results
Start Over Author "Joseph JY Sung" Publication Year Range Last 3 years
14 results on '"Joseph JY Sung"'

2. The combined role of MRI prostate and prostate health index in improving detection of significant prostate cancer in a screening population of Chinese men

Author

Peter KF Chiu, Thomas YT Lam, Chi-Fai Ng, Jeremy YC Teoh, Carmen CM Cho, Hiu-Yee Hung, Cindy Hong, Monique J Roobol, Winnie CW Chu, Samuel YS Wong, and Joseph JY Sung

Subjects
magnetic resonance imaging prostate, prostate cancer, prostate health index, prostate-specific antigen, screening, Diseases of the genitourinary system. Urology, RC870-923
Abstract

Using prostate-specific antigen (PSA) for prostate cancer (PCa) screening led to overinvestigation and overdiagnosis of indolent PCa. We aimed to investigate the value of prostate health index (PHI) and magnetic resonance imaging (MRI) prostate in an Asian PCa screening program. Men aged 50–75 years were prospectively recruited from a community-based PSA screening program. Men with PSA 4.0–10.0 ng ml−1 had PHI result analyzed. MRI prostate was offered to men with PSA 4.0–50.0 ng ml−1. A systematic prostate biopsy was offered to men with PSA 4.0–9.9 ng ml−1 and PHI ≥35, or PSA 10.0–50.0 ng ml−1. Additional targeted prostate biopsy was offered if they had PI-RADS score ≥3. Clinically significant PCa (csPCa) was defined as the International Society of Urological Pathology (ISUP) grade group (GG) ≥2 or ISUP GG 1 with involvement of ≥30% of total systematic cores. In total, 12.8% (196/1536) men had PSA ≥4.0 ng ml−1. Among 194 men with PSA 4.0–50.0 ng ml−1, 187 (96.4%) received MRI prostate. Among them, 28.3% (53/187) had PI-RADS ≥3 lesions. Moreover, 7.0% (107/1536) men were indicated for biopsy and 94.4% (101/107) men received biopsy. Among the men received biopsy, PCa, ISUP GG ≥2 PCa, and csPCa was diagnosed in 42 (41.6%), 24 (23.8%), and 34 (33.7%) men, respectively. Compared with PSA/PHI pathway in men with PSA 4.0–50.0 ng ml−1, additional MRI increased diagnoses of PCa, ISUP GG ≥2 PCa, and csPCa by 21.2% (from 33 to 40), 22.2% (from 18 to 22), and 18.5% (from 27 to 32), respectively. The benefit of additional MRI was only observed in PSA 4.0–10.0 ng ml−1, and the number of MRI needed to diagnose one additional ISUP GG ≥2 PCa was 20 in PHI ≥35 and 94 in PHI

Published
2023
Full Text
View/download PDF

5. Randomized controlled trials of artificial intelligence in clinical practice: A systematic review (Preprint)

Author

Thomas YT Lam, Max FK Cheung, Yasmin L Munro, Kong Meng Lim, Dennis Shung, and Joseph JY Sung

Abstract

BACKGROUND The number of artificial intelligence (AI) studies in medicine has exponentially increased recently. However, there is no clear quantification of clinical benefit when AI-assisted tools are implemented in patient care. OBJECTIVE We aim to systematically review all published randomized controlled trials (RCTs) of AI-assisted tools to characterize their performance in clinical practice. METHODS CINAHL, Cochrane Central, Embase, Medline and PubMed were searched to identify relevant RCTs comparing the performance of AI-assisted tool against conventional clinical management without AI-assistance published up to July 2021. We evaluated the primary endpoints of each study to determine which were clinically relevant. RESULTS Among 11,839 articles searched, only 38 RCTs identified were included. These RCTs were conducted in a roughly equal distribution from North America, Europe, and Asia. AI-assisted tools were implemented in 13 different clinical specialties. Most RCTs were published in the field of Gastroenterology, with 15 studies on AI-assisted endoscopy. The majority of RCTs studied image-based AI-assisted tools, and a minority of RCTs studied AI-assisted tools that drew from tabular patient. In 29 out of 38 RCTs, AI-assisted interventions outperformed usual clinical care, and clinically relevant outcomes improved with AI assisted intervention in 21 out of 29 studies. Small sample size and single-centre design limit the generalizability of these studies. CONCLUSIONS There is growing evidence supporting the implementation of AI-assisted tool in daily clinical practice, yet the number of available RCTs is limited and heterogeneous. Future studies are needed to quantify the benefit of AI-assisted tools in clinical practice. CLINICALTRIAL This study was registered on PROSPERO (ID: CRD42021286539).

Published
2022
Full Text
View/download PDF

6. ARTIFICIAL INTELLIGENCE ASSISTED COLONOSCOPY FOR ADENOMA DETECTION IN SCREENING COLONOSCOPY: A MULTI-CENTRE RANDOMIZED CONTROLLED STUDY

Author

Hong Xu, Raymond S. Tang, Thomas Y. Lam, Guijun Zhao, James Y. Lau, Yunpeng Liu, Qi Wu, Long Rong, Weiran Xu, Xue Li, Sunny H. Wong, Shuntian Cai, Jing Wang, Guanyi Liu, Tantan Ma, Xiong Liang, Joyce W. Mak, Hongzhi Xu, Peng Yuan, TingtIng Cao, Hong Zhu, Zhenshi Ye, and Joseph JY. Sung

Subjects
Gastroenterology, Radiology, Nuclear Medicine and imaging
Published
2022
Full Text
View/download PDF

7. Artificial Intelligence in Medicine : From Ethical, Social, and Legal Perspectives

Author

Joseph JY Sung, Cameron Stewart, Joseph JY Sung, and Cameron Stewart

Subjects
Artificial intelligence--Moral and ethical aspects, Artificial intelligence--Medical applications, Artificial intelligence--Law and legislation
Abstract

Although AI is opening new and exciting opportunities in healthcare, implementation still faces challenges. Artificial Intelligence in Medicine: From Ethical, Social, and Legal Perspectives provides answers on how to improve acceptance and diminish the anxiety of the use of AI-assisted medicine. Through a series of social, ethical, and legal discussions from clinicians, social scientists, ethicists, and legal experts this important reference has coverage that includes good data custodianship and stewardship; data access, data bias, data & healthcare equity; privacy and confidentiality; algorithmic understanding; and regulatory guidance, accountability, and legal responsibility. This reference will explain to healthcare providers how AI will enhance healthcare, will introduce to scientists and researchers the ethical and social aspect of AI that needs to be addressed, and will urge policymakers and health authorities to consider the legal framework needed to implement AI technology in healthcare. - Discusses the issues that must be addressed to improve acceptance and diminish the anxiety and lack of trust surrounding the care of human health by machines - Examines the delicate issues surrounding the use of AI in making life-and-death decisions - Sets the framework of social, ethical, and legal aspects of healthcare for the future

Published
2024

12. Su1066: IMPACT OF COVID-19 ON THE CLINICAL OUTCOMES AND MANAGEMENT OF IGG4 RELATED DISEASE PATIENTS WITH PANCREATOBILIARY INVOLVEMENT: A MULTICENTER RETROSPECTIVE STUDY

Author

Raymond S Tang, Onuma Sattayalertyanyong, Kenneth H. Park, Constantinos Anastassiades, Dario Ligresti, Nobuhiko Hayashi, Aws Hasan, Ting Ting Chan, Nonthalee Pausawasdi, Simon K. Lo, Khek-Yu Ho, Luca Barresi, Mario Traina, Ichiro Yasuda, Thomas J. Savides, Thomas Y. Lam, and Joseph JY Sung

Subjects
Hepatology, Gastroenterology
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results